Sandoz Gets EU Nod For Higher-Strength Adalimumab
CHMP Also Endorses Generics From Accord, Sun And Viatris At January Meeting
Sandoz has received a positive opinion from the EMA’s CHMP recommending that its high-concentration 100mg/ml adalimumab biosimilar be granted a pan-European marketing authorization. Three generics were also endorsed at the CHMP’s January meeting, including a rival to Forxiga.
